You are here: Industry Insights > MedImmune

News List

AZ’ Imfinzi fails in head and neck cancer trial pharmatimes
December 10, 2018
AstraZeneca and MedImmune’s Imfinzi has failed to hit targets in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
AZ signs up for access to Compugen’s pipeline pharmatimes
July 19, 2018
AstraZeneca’s MedImmune has inked a deal with Israeli group Compugen giving it access to the firm’s experimental bi- and multi-specific antibody products.
AstraZeneca, MedImmune and Ethris to develop mRNA treatments for respiratory diseases pharmaceutical-technology
August 22, 2017
AstraZeneca, along with its global biologics research and development unit MedImmune, and German biotech Ethris have entered a strategic research collaboration to develop stabilised non-immunogenic modified messenger ribonucleic acid (mRNA) therapies for
Imfinzi significantly reduces the risk of disease worsening or death in the Phase III PACIFIC trial worldpharmanews
May 15, 2017
AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive results for the Phase III PACIFIC trial, a randomised, double-blinded...
Sanofi Pasteur and MedImmune to develop and commercialise MEDI8897 pharmaceutical-technology
March 07, 2017
French-based Sanofi Pasteur has signed an agreement with AstraZeneca’s global biologics research and development arm MedImmune to develop and commercialise a monoclonal antibody known as MEDI8897.
Sanofi Pasteur and MedImmune Collaborate on Monoclonal Antibody to Prevent Illnesses Associated with americanpharmaceuticalreview
March 06, 2017
Sanofi and its vaccines global business unit Sanofi Pasteur announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca,